PDF
ePub
Citation
Print
Abstract
Premenstrual syndrome(PMS) refers to a group of menstruation- related symptoms that impair daily activity and interpersonal relationship. The therapeutic modality for PMS consists of non-pharmacologic and pharmacologic treatment. Generally, after confirmation of PMS, a set of non-pharmacologic treatments is recommended before pharmacologic treatment. Patients can be benefited from non-pharmacological treatments such as patient education, cognitive therapy, behavioral therapy, and dietary supplementation. Pharmacologic therapy including psychotropic agents, diuretics, and prostaglandin inhibitors may be used, when PMS symptoms are not sufficiently improved after non-pharmacologic treatments, or when symptoms fit the diagnostic criteria of premenstrual dysphoric disorder(PMDD). When treatment fails, hormonal therapy to manipulate menstrual cycle may be considered, and several trials showed improvement of physical and mood symptoms.
References
1. Logue CM, Moos RH. Perimenstrual symptoms: prevalence and risk factors. Psychosom Med. 1986. 48:388–414.
2. Moline ML, Zendell SM. Evaluating and managing premenstrual syndrome. Medscape Womens Health. 2000. 5:1–16.
3. Daugherty JE. Treatment strategies for premenstrual syndrome. Am Fam Physician. 1998. 58:183–192. 197–198.
4. Freeman EW, Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry. 1999. 156:1403–1408.
5. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Harrison W, et al. Sertraline Premenstrual Dysphoric Collaborative Study Group. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment A randomized controlled trial. JAMA. 1997. 278:983–988.
6. Goodale IL, Domar AD, Benson H. Alleviation of premenstrual syndrome symptoms with the relaxation response. Obstet Gynecol. 1990. 75:649–655.
7. Johnson WG, Carr-Nangle RE, Bergeron KC. Macronutrient intake, eating habits, and exercise as moderators of menstrual distress in healthy women. Psychosom Med. 1995. 57:324–330.
8. Plouffe L Jr, Stewart K, Craft KS, Maddox MS, Rausch JL. Diagnostic and treatment results from a southeastern academic center-based premenstrual syndrome clinic: the first year. Am J Obstet Gynecol. 1993. 169:295–307.
9. American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice. Premenstrual syndrome. ACOG committee opinion no. 155. Int J Gynecol Obstet. 1995. 50:80–84.
10. Sayegh R, Schiff I, Wurtman J, Spiers P, McDermott J, Wurtman R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol. 1995. 86:520–528.
11. Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999. 318:1375–1381.
12. London RS, Murphy L, Kitlowski KE, Reynolds MA. Efficacy of alpha-tocopherol in the treatment of the premenstrual syndrome. J Reprod Med. 1987. 32:400–404.
13. Thys-Jacobs S, Starkey P, Bernstein D, Tain J. Premenstrual Syndrome Study Group. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol. 1998. 179:444–452.
14. Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998. 7:1157–1165.
15. Khoo SK, Munro C, Battistutta D. Evening primrose oil and treatment of premenstrual syndrome. Med J Aust. 1990. 153:189–192.
16. Budeiri D, Li Wan, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome? Control Clin Trials. 1996. 17:60–68.
17. Freeman EW, Rickels K, Arredondo F, Kao LC, Pollack SE, Sondheimer SJ. Full-or half cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol. 1999. 19:3–8.
18. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000. 356:1131–1136.
19. ACOG practice Bulletin. Clinical management guidelines for obstetrician-gynecologist Number 15 April 2000. Premenstrual syndrome. Obstet Gynecol. 2000. 95:1–9.
20. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull. 1997. 33:771–774.
21. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Eriksson E, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998. 18:390–398.
22. Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol. 1987. 70:37–43.
23. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993. 9:133–145.
24. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind placebo-controlled study. Acta Obstet Gynecol Scand. 1995. 74:803–808.
25. Gunston KD. Premenstrual syndrome in Cape Town. Part II. A double-blind placebo-controlled study of the efficacy of mefenamic acid. S Afr Med J. 1986. 70:159–160.
26. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol. 1999. 180:18–23.
27. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology. 1995. 20:193–209.
28. Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol. 1994. 84:779–786.
29. Sundstrom I, Nyberg S, Bixo M, Hammarback S, Backstrom T. Treatment of remenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand. 1999. 78:891–899.
30. Di Carlo C, Palomba S, Tommaselli GA, Guida M, Di Spiezio Sardo A, Naooi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril. 2001. 75:380–384.
31. Leather AT, Studd JW, Watson NR, Holland EF. The treatment of severe premenstrual syndrome with goserelin with and without add-back estrogen therapy: a placebo-controlled study. Gynecol Endocrinol. 1999. 13:48–55.
32. Taskin O, Gokdeniz R, Yalcinoglu A, Buhur A, Burak F, Ozekici V, et al. Placebo-controlled cross-over study of effects of tibolone on premenstrual symptoms and peripheral beta-endorphin concentrations in premenstrual syndrome. Hum Reprod. 1998. 13:2402–2405.
33. Andersch B, Hahn L. Premenstrual complaints II. Influence of oral contraceptives. Acta Obstet Gynecol Scand. 1981. 60:579–583.
34. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology. 1993. 18:273–281.
35. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001. 10:561–569.
36. Dickerson LM, Mazyck PJ, Hunter MH. Premenstrual syndrome. Am Fam Physician. 2003. 67:1743–1752.
37. Braiden V, Metcalf G. Premenstrual tension among hysterectomized women. J Psychosom Obstet Gynaecol. 1995. 16:145–151.
XML Download